Evaluation of HMG-CoA Reductase Inhibitors for Multiple Sclerosis
The disease-modifying agents currently used in the treatment of multiple sclerosis (MS) are not completely effective and are associated with adverse effects and high costs. Thus, alternative treatment options are highly desirable. HMG-CoA reductase inhibitors (statins), widely prescribed as cholesterol-lowering agents, may be a future treatment option for MS — either in an add-on therapy regimen or alone — as they have been shown to exhibit potent immunomodulatory effects. Several recent reports have demonstrated that HMG-CoA reductase inhibitors prevent and reverse chronic and relapsing experimental autoimmune encephalomyelitis, an animal model of MS. Furthermore, in vitro experiments with human immune cells have shown an immunomodulatory mode of action of HMG-CoA reductase inhibitors that is comparable to that of interferon-β, an established treatment for MS. An open-label clinical trial assessing simvastatin treatment in patients with MS revealed a significant decrease in the number and volume of new lesions, as assessed using magnetic resonance imaging, and a favourable safety profile. A large multicentre, placebo-controlled phase II clinical trial assessing atorvastatin in patients with a clinically isolated syndrome (i.e. a single clinical event that is indicative of demyelination, and that predisposes to the development MS) has recently been initiated. However, prospective placebo-controlled trials of HMG-CoA reductase inhibitors in definite MS are difficult to perform because of ethical and financial issues. Furthermore, overly optimistic reports in the popular media, as well as the often uncontrolled access to HMG-CoA reductase inhibitors by patients with MS, complicate the evaluation of HMG-CoA reductase inhibitors as a realistic future treatment option for MS.
KeywordsMultiple Sclerosis Simvastatin Atorvastatin Experimental Autoimmune Encephalomyelitis Lovastatin
No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest to disclose.
- 12.The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993 Apr; 43(4): 655–61Google Scholar
- 13.Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in exacerbating-remitting multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996 Mar; 39(3): 285–94Google Scholar
- 15.Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995 Jul; 45(7): 1268–76Google Scholar
- 27.Ridker PM. Connecting the role of C-reactive protein and statins in cardiovascular disease. Clin Cardiol 2003 Apr; 26(4 Suppl. 3): 11139–44Google Scholar
- 35.Kurakata S, Kada M, Shimada Y, et al. Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro. Immunopharmacology 1996 Aug; 34(1): 51–61PubMedCrossRefGoogle Scholar
- 58.Daumer M, Kessner S, Lederer C, et al. Modelling placebo groups for clinical trials [abstract]. Mult Scier 2003 Sep; 9Suppl 1): S22Google Scholar
- 59.Pilcher HR. Statins may curb multiple sclerosis. Nature News Service: Macmillan Magazines Ltd, 2004 May 14Google Scholar
- 61.Stüve O, Youssef S, Dunn S, et al. Atorvastatin enhances the clinically beneficial effects of glatiramer acetate in experimental autoimmune encephalomyelitis through induction of a TH2 phenotype [abstract]. Neurology 2004 Apr 13; 62(Suppl 5) (7): A438Google Scholar